[Toxicity of high-dose bleomycin administered by continuous infusion]

Area of Science:

• Oncology
• Pharmacology

Background:

• Nonseminomatous testicular cancer requires effective treatment regimens.
• Multidrug chemotherapy is a standard approach for this malignancy.

Purpose of the Study:

• To evaluate the efficacy and toxicity of a specific multidrug regimen for nonseminomatous testicular cancer.
• To assess the impact of bleomycin administration on pulmonary and cutaneous toxicity.

Main Methods:

• Fifteen patients with nonseminomatous testicular cancer received treatment with cis platinum, Velban, and bleomycin.
• Bleomycin was administered in monthly 5-day courses at 100 mg/m2.
• Efficacy was measured by remission rates (complete and partial).
• Pulmonary function was assessed via arterial oxygen pressure and Tiffeneau index.
• Cutaneous toxicity and oral mucosa damage were also monitored.

Main Results:

• Twelve out of 15 patients achieved remission (10 complete, 2 partial), indicating significant antitumor effect.
• Pulmonary toxicity was minimal, with normal lung X-rays and functional parameters post-treatment.
• Median arterial oxygen pressure was 78 mm Hg and median Tiffeneau index was 84.
• Cutaneous toxicity was low, with only 2 patients experiencing skin marks.
• Reversible oral mucosa damage occurred in 2 patients; alopecia was common.

Conclusions:

• The combination of cis platinum, Velban, and bleomycin demonstrates high efficacy in treating nonseminomatous testicular cancer.
• This regimen is associated with significantly reduced pulmonary and cutaneous toxicity.
• Bleomycin can be administered effectively with manageable side effects, making it a viable option in testicular cancer treatment.